Early Systemic Central Nervous System Prophylaxis in Diffuse Large B-cell Lymphoma

A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma

NCT03758989 ·Status: RECRUITING ·Phase: PHASE2

A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma

NCT03003520 ·Status: COMPLETED ·Phase: PHASE2

High-dose Intravenous Methotrexate Versus Intrathecal Methotrexate for Central Nervous System Prophylaxis in DLBCL

NCT03123718 ·Status: UNKNOWN ·Phase: PHASE3

Study of Epcoritamab in R/R Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and Rituximab

NCT06931652 ·Status: RECRUITING ·Phase: PHASE2

A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

NCT02957019 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma

NCT05459571 ·Status: COMPLETED ·Phase: PHASE2

Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

NCT01197560 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT02077166 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

A Phase II Study of Oral Panobinostat (LBH589) and Rituximab to Treat Diffuse Large B Cell Lymphoma (DLBCL)

NCT01238692 ·Status: COMPLETED ·Phase: PHASE2

Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

NCT00295932 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT04285268 ·Status: WITHDRAWN ·Phase: PHASE2

Panobinostat With Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma

NCT01282476 ·Status: TERMINATED ·Phase: PHASE2

Outpatient Epcoritamab as 2L in NTE R/R DLBCL

NCT06811272 ·Status: RECRUITING ·Phase: PHASE2

Methotrexate and Temozolomide Versus Methotrexate, Procarbazine, Vincristine and Cytarabine

NCT00503594 ·Status: UNKNOWN ·Phase: PHASE2

Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma

NCT02073097 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Bruton's Tyrosine Kinase (BTK) Inhibition in B-cell Lymphomas

NCT02055924 ·Status: TERMINATED ·Phase: PHASE1

Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

NCT03206970 ·Status: COMPLETED ·Phase: PHASE2

Study of Rituximab Plus High-Dose Chemotherapy Poor Prognosis Non-Hodgkin's Lymphoma

NCT00141700 ·Status: TERMINATED ·Phase: PHASE2

S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma

NCT01359592 ·Status: COMPLETED ·Phase: PHASE2

A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma

NCT07189065 ·Status: RECRUITING ·Phase: PHASE2

Reduction of MTX Levels After Glucarpidase Treatment in DLBCL Patients at Risk of CNS

NCT05022797 ·Status: TERMINATED ·Phase: PHASE2

CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant

NCT06687772 ·Status: RECRUITING ·Phase: PHASE2

Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms

NCT04858256 ·Status: RECRUITING ·Phase: PHASE2

Study of Entospletinib (ENTO) in Newly Diagnosed DLBCL Patients With aaIPI>=1 Treated by Chemiotherapy

NCT03225924 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma

NCT03161223 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2